Human ADAM8 Ectodomain Antibody Summary
Glu158-Ser653
Accession # P78325
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
ADAM8 in Human PBMCs. ADAM8 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human ADAM8 Ectodomain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1031) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasmic. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: ADAM8
ADAM8, also known as cell surface antigen MS2 or CD156a, is a member of the ADAM family that contains a disintegrin and metalloprotease-like domain (1, 2). ADAM8 can cleave a variety of substrates and has been shown as a sheddase for the low affinity IgE receptor CD23 and the neural recognition molecule CHL1 (3, 4). Expression and regulation studies suggest that ADAM8 is a novel osteoclast stimulating factor and may play a role in asthma (5, 6). The 824 amino acid precursor of human ADAM8 consists of a signal peptide (residues 1 to 16), a pro peptide (residues 17 to 199), a metaloprotease domain (residues 200 to 400), a disintegrin-like domain (residues 408 to 494), a cysteine-rich region (residues 497 to 613), an EGF-like domain (residues 614 to 640), a transmembrane region (residues 656 to 676) and a cytoplasmic domain (residues 677 to 824).
- Yoshiyama, K. et al. (1997) Genomics 41:56.
- Moss, M.L. and J.W. Bartsch (2004) Biochemistry 43:7227.
- Fourie, A.M. et al. (2003) J. Biol. Chem. 278:30469.
- Naus, S. et al. (2004) J. Biol. Chem. 279:16083.
- Choi, S.J. et al. (2001) J. Bone Miner. Res. 16:814.
- King, N.E. et al. (2004) Am. J. Respir. Cell Mol. Biol. 31:257.
Product Datasheets
Citations for Human ADAM8 Ectodomain Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
6
Citations: Showing 1 - 6
Filter your results:
Filter by:
-
RNA Aptamer Targeting of Adam8 in Cancer Growth and Metastasis
Authors: Mi, Z;Kuo, MC;Kuo, PC;
Cancers
Species: Human
Sample Types: Whole Cells
Applications: Neutralization -
ADAM8 signaling drives neutrophil migration and ARDS severity
Authors: C Conrad, D Yildiz, SJ Cleary, A Margraf, L Cook, U Schlomann, B Panaretou, JL Bowser, H Karmouty-Q, J Li, NK Berg, SC Martin, A Aljohmani, SF Moussavi-H, KM Wang, JJ Tian, M Magnen, C Valet, L Qiu, JP Singer, HK Eltzschig, CAPSys Stu, W Bertrams, S Herold, N Suttorp, B Schmeck, ZT Ball, A Zarbock, MR Looney, JW Bartsch
JCI Insight, 2022-02-08;7(3):.
Species: Human
Sample Types: Whole Cells, Whole Tissue
Applications: Flow Cytometry, ICC, IHC -
Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma
Authors: C Jaworek, Y Verel-Yilm, S Driesch, S Ostgathe, L Cook, S Wagner, DK Bartsch, EP Slater, JW Bartsch
Journal of personalized medicine, 2021-02-10;11(2):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression
Authors: K Theodorou, EPC van der Vo, MJ Gijbels, IMJ Wolfs, M Jeurissen, TL Theelen, JC Sluimer, E Wijnands, JP Cleutjens, Y Li, Y Jansen, C Weber, A Ludwig, JF Bentzon, JW Bartsch, EAL Biessen, MMPC Donners
Sci Rep, 2017-09-15;7(1):11670.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
ADAM8 as a drug target in pancreatic cancer.
Authors: Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia A, Hofling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem R, Moss M, Rasmussen F, Miller M, Lauffenburger D, Tuveson D, Nimsky C, Bartsch J
Nat Commun, 2015-01-28;6(0):6175.
Species: Human
Sample Types: Whole Cells
Applications: Immunoprecipitation, Native SDS-PAGE -
Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.
Authors: Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grenman R, James HA, Edwards DR, Kahari VM
Clin. Cancer Res., 2010-03-21;16(0):2022.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsIsotype Controls
Reconstitution Buffers
Secondary Antibodies
Reviews for Human ADAM8 Ectodomain Antibody
Average Rating: 5 (Based on 1 Review)
Have you used Human ADAM8 Ectodomain Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
